|
Price: $240.6900
$-4.92 
-2.003%
|
| Day's High:
| $250.145
| Week Perf:
| -3.86 %
|
| Day's Low: |
$ 239.87 |
30 Day Perf: |
-4.69 % |
| Volume (M): |
247 |
52 Wk High: |
$ 348.67 |
| Volume (M$): |
$ 59,450 |
52 Wk Avg: |
$258.27 |
| Open: |
$247.13 |
52 Wk Low: |
$144.76 |
|
|
| Market Capitalization (Millions $) |
9,435 |
| Shares
Outstanding (Millions) |
39 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
938 |
| Net Income (TTM) (Millions $) |
29 |
| Cash Flow (TTM) (Millions $) |
45 |
| Capital Exp. (TTM) (Millions $) |
15 |
Penumbra Inc
Penumbra Inc. is a California-based medical device company that's focused on the development and manufacturing of innovative medical technologies for the treatment of neurological and vascular disorders. The company's portfolio of products includes neurovascular access, neurovascular intervention, neurointensive care, and related products for stroke and neurovascular disorders, including cerebral aneurysms, intracranial atherosclerosis, and traumatic brain injury.
Penumbra's history can be traced back to 2004 when it was founded by Dr. Adam Elsesser, an entrepreneur with a background in neuroscience and neurointervention. The company's name derives from the Latin word "penumbra," which refers to the partial shadow surrounding an area of complete darkness, symbolizing Penumbra's mission to bring light to dark and complex medical issues.
The company's flagship product, the Penumbra System, is a mechanical thrombectomy device that's used to remove blood clots from the brain during an ischemic stroke. This device has been a game-changer in the treatment of stroke, providing a safe and efficient alternative to traditional clot-busting drugs. Other notable products in Penumbra's portfolio include the 3D Revascularization Device, which provides mechanical support for the stent during large-vessel or complex aneurysm treatment, and the Neuron MAX System, which is used for rapid sealing of puncture holes following diagnostic or interventional neurovascular procedures.
In addition to its portfolio of medical devices, Penumbra has also developed a line of neurointensive care products, including catheters, drainage systems, and other devices that aid in the management of critically ill patients with neurological disorders. These products are designed to optimize patient outcomes and reduce complications during the recovery process.
Penumbra is committed to innovation and invests heavily in research and development to advance the quality and efficacy of its products. The company's state-of-the-art manufacturing and research facilities are located in Alameda, California, and its products are sold in over 100 countries worldwide.
Penumbra has won numerous awards and recognitions for its contributions to the field of medical technology, including the Galien USA Award for Best Medical Technology in 2011 and 2015. The company's commitment to excellence and innovation has helped make it a leader in the medical device industry and a driving force in the fight against neurovascular disorders.
Company Address: One Penumbra Place Alameda 94502 CA
Company Phone Number: 748-3200 Stock Exchange / Ticker: NYSE PEN
| PEN is expected to report next financial results on November 02, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Heart Test Laboratories Inc
Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
|
|
Sensasure Technologies Inc
Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.
|
|
Innovage Holding Corp
Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.
|
|
Lakeland Industries Inc
Lakeland Industries Inc, a leading Medical Equipment and Supplies company, has delivered impressive financial results for the most recent fiscal period, outpacing its industry contemporaries. The company reported a positive bottom-line of $0.32 per share, a significant improvement compared to the negative $0.11 per share from the previous year. This translates to a staggering 77.78% increase in earnings per share from $0.18 in the previous reporting period.
The revenue growth for Lakeland Industries Inc has been equally impressive, with a substantial increase of 17.34% to $33.07 million from $28.18 million in the corresponding period a year ago. Moreover, their sequential revenue growth improved by 15.23% from $28.70 million. In sharp contrast, the rest of the Medical Equipment and Supplies industry only witnessed a 4.18% revenue improvement during the same period. This clearly highlights Lakeland Industries Inc's exceptional performance in the market.
|
|
The Cooper Companies Inc
Medical Equipment and Supplies Company, The Cooper Companies Inc, experienced a decline in earnings per share (EPS) despite a rise in revenue for the financial period ending on July 31, 2023. Although revenue increased by a significant 10.268% to $930.00 million compared to the previous year, income fell by -13.64% to $1.71 per share.
Despite the decline in EPS, the company's revenue surge in the third quarter of 2023 surpassed its industry peers, which only experienced a 4.05% overall business increase during the same period. Comparing to the previous reporting period, EPS showed impressive growth of 113.75% from $0.80 per share, while revenue improved by 5.995% from $877.40 million.
However, net earnings declined by -13.31% to $85.300 million at the end of July, compared to $98.400 million in the same period a year earlier. The Cooper Companies Inc focused on improving sales during the financial period, leading to a net margin decrease to 9.17%. Additionally, there has been a noticeable buildup in inventories, with inventories and supplies reaching $723.6 million, higher than the previous and corresponding quarter of the previous year.
On a positive note, operating earnings rose by 7.82% to $151.6 million. The increase in accounts receivable also indicates rising demand, with a value of $629.9 million, higher than the preceding quarter.
Looking into the future performance, The Cooper Companies Inc shares recorded a decline of -0.19% over the past five trading days, resulting in a year-to-date performance of 11.63%. The shares are currently 7.1% short of the 52-week highInvestors will be eagerly waiting to see the next financial numbers from The Cooper Companies Inc, which are expected to be reported on December 08, 2023. With a focus on improving sales and a noticeable buildup in inventories and accounts receivable, the company may be positioning itself for future growth despite the recent decline in EPS.
|
| Per Share |
Current |
| Earnings (TTM) |
0.74 $ |
| Revenues (TTM) |
23.92 $
|
| Cash Flow (TTM) |
1.16 $ |
| Cash |
5.64 $
|
| Book Value |
27.21 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.74 $
|
| Revenues (TTM) |
23.92 $ |
| Cash Flow (TTM) |
1.16 $ |
| Cash |
5.64 $
|
| Book Value |
27.21 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
